[1] Andtbacka RH, Kaufman HL, Collichio F, et al.Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma[J]. J Clin Oncol, 2015, 33(25): 2780-2788. [2] Harrington K, Freeman DJ, Kelly B, et al.Optimizing oncolytic virotherapy in cancer treatment[J]. Nat Rev Drug Discov, 2019, 18(9): 689-706. [3] Davola ME, Mossman KL.Oncolytic viruses: how“lytic”must they be for therapeutic efficiency[J]. Oncoimmunology, 2019, 8(6): e1581528. [4] Huang HY, Lu YY, Xie Z.Progress of oncolytic viruses in cancer therapy[J]. Infect Dis Info(传染病信息), 2019, 32(1): 30-36. [5] Hill C, Carlisle R.Achieving systemic delivery of oncolytic viruses[J]. Expert Opin Drug Deliv, 2019, 16(6): 607-620. [6] FDA. Guidance for industry: preclinical assessment of investigational cellular and gene therapy products [EB/OL].[2021-02-07]. https://www.fda.gov/media/87564/download. [7] Centre for Drug Evaluation, NMPA. Guidance for single dose toxicity testing for pharmaceuticals[EB/OL]. (2014-05-13) [2021-02-07].http://www.cde.org.cn/zdyz.do?method=largePage&id=75c870924b8a52af. [8] Centre for Drug Evaluation, NMPA. Guidance for repeat dose toxicity testing for pharmaceuticals[EB/OL]. (2014-05-13) [2021-02-07]. http://www.cde.org.cn/zdyz.do?method=largePage&id=abf139c330d74064. [9] Zhang CX, Sauder C, Malik T, et al.A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines[J]. Biologicals, 2010, 38(2): 278-283. [10] Russell L, Peng KW, Russell SJ, et al.Oncolytic viruses: priming time for cancer immunotherapy[J]. BioDrugs, 2019, 33(5): 485-501. [11] Koske I, Rössler A, Pipperger L, et al.Oncolytic virotherapy enhanced the efficiency of a cancer vaccine by modulating the tumor microenvironment[J]. Int J Cancer, 2019, 145(7): 1958-1969. [12] Twumasi-Boateng K, Pettigrew JL, Kwok YYE, et al.Oncolytic viruses as engineering platforms for combination immunotherapy[J]. Nat Rev Cancer, 2018, 18(7): 419-432. [13] Tang L, Li PC, Li RF, et al.Advances on the regulation of tumor microenvironment and combination therapy by oncolytic viruses[J]. Progress in Biochemistry and Biophysics(生物化学与生物物理进展), 2020, 47(5): 399-406. [14] Sobol PT, Boudreau JE, Stephenson K, et al.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy[J]. Mol Ther, 2011, 19(2): 335-344. [15] Ricca JM, Oseledchyk A, Walther T, et al.Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy[J]. Mol Ther, 2018, 26(4): 1008-1019. [16] Pelin A, Wang J, Bell J, et al.The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses[J]. Oncolytic Virother, 2017(7): 25-35. [17] Haworth R, Pilling AM.The PCR assay in the preclinical safety evaluation of nucleic acid medicines[J]. Hum Exp Toxicol, 2000, 19(5): 267-276. [18] FDA. Guidance for industry: design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products [EB/OL].[2021-2-07]. https://www.fda.gov/media/89036/download. [19] ICH. M6: guideline on virus and gene therapy vector shedding and transmission [EB/OL].[2021-02-07]. https://database.ich.org/sites/default/files/M6_Concept_Paper.pdf. [20] Macedo N, Miller DM, Haq R, et al.Clinical landscape of oncolytic virus in 2020[J]. J Immunother Cancer, 2020, 8(2):1-14. [21] Wang Z, Jay CM, Evans C, et al.Preclinical biodistribution and safety evaluation of a pbi-shRNA STMN1 lipoplex after subcutaneous delivery[J]. Toxicol Sci, 2017, 155(2): 400-408. [22] Wang YL.The post-marketing surveillance of human papilloma virus vaccine[J]. Chinese Journal of Pharamacovigilance(中国药物警戒), 2017, 14(7): 439-442. |